Controversy about the Role of Rifampin in Biofilm Infections: Is It Justified?

Area of Science:

• Infectious Diseases
• Orthopedic Surgery
• Pharmacology

Background:

• Staphylococcal implant-associated infections pose significant clinical challenges.
• Rifampin is a key antibiotic for staphylococcal infections, especially those involving biofilms.
• Concerns exist regarding rifampin resistance and drug interactions.

Purpose of the Study:

• To review evidence on rifampin's efficacy in staphylococcal implant-associated infections.
• To critically evaluate recent clinical trial data regarding rifampin use.
• To discuss the ethical considerations of future research.

Main Methods:

• Review of preclinical data from animal models of foreign-body infections.
• Analysis of existing clinical trial evidence.
• Critical appraisal of a recent randomized controlled trial (RCT) on periprosthetic joint infections.

Main Results:

• Rifampin demonstrates potent activity against staphylococcal implant infections and biofilm-related infections.
• A recent RCT showed no benefit of rifampin in acute staphylococcal periprosthetic joint infection with prosthesis retention.
• The risk of rifampin resistance and drug interactions remains a concern.

Conclusions:

• Abundant evidence supports rifampin's benefit in biofilm-related and implant-associated staphylococcal infections.
• The interpretation of conflicting trial data requires careful consideration of existing evidence.
• Conducting further large-scale RCTs may be ethically questionable given the established efficacy of rifampin.